You cannot advertise prescription medicines to the public in Australia. Prescription-only (Schedule 4) and controlled (Schedule 8) medicines cannot be named or promoted in any ad aimed at the public. That covers the brand name, the active ingredient, and any clear reference to the product, on your website, social media, emails, or a blog. You can still advertise the health service. You can say your clinic offers consultations to discuss options, who provides them, and how to book, as long as the ad never names or points to a prescription medicine. The advertiser is liable, which includes the agency and the copywriter, not only the business.
Key takeaways
- Prescription medicines (Schedule 4 and Schedule 8) cannot be advertised to the public at all. This is the strictest line in the system.
- The ban covers the brand name, the active ingredient, and any clear reference to the product.
- You can advertise the consultation or service. A service is not a therapeutic good, so the goods rules do not catch it, as long as you do not name the medicine.
- An "educational" blog post does not escape the rule. If it promotes use or supply of the medicine, it is an ad.
- The advertiser is liable. That includes the agency and the copywriter, not only the business.
What is the rule?
The rule is short. You cannot advertise prescription medicines to the public in Australia. It is one of the clearest lines in the whole compliance system, and it is also the one I see broken most.
It sits in the Therapeutic Goods Act 1989 and the Therapeutic Goods Advertising Code 2021, run by the Therapeutic Goods Administration (TGA). Prescription-only medicines sit in Schedule 4 of the Poisons Standard. Controlled medicines sit in Schedule 8. Neither group can be advertised to the public.
This is the foundational TGA rule. Almost every other prescription-substance question, weight-loss medicines, medicinal cannabis, injectables, hormone treatments, comes back to this one line. Get this right and the rest follows. For the full picture of how the code works, start with my guide to the TGA advertising code in 2026.
The core idea: a prescription medicine should be chosen by a doctor for one patient. It should never be sold to the public by an ad. That single idea explains the whole rule.
Why are prescription medicines off limits?
The logic is about who decides. A prescription medicine carries real risks. It needs a doctor to weigh those risks for one person, with that person's history in front of them.
If you let companies advertise these medicines straight to the public, you create demand for a serious drug through marketing, not medicine. People start asking for a product by name before anyone has checked whether it suits them. Australia, like most countries outside the United States and New Zealand, decided that is the wrong way round. So the law blocks it at the source.
That is why the ban is so wide. It is not just "do not say buy this drug". It is "do not promote this drug to the public at all".
What counts as advertising a prescription medicine?
This is where good marketers get caught. The TGA defines an advertisement as anything that promotes the use or supply of a therapeutic good. That is a broad net, and it catches far more than a paid ad.
You are advertising a prescription medicine if you name or point to it in any of these:
- The brand name. The obvious one. If the product has a trade name, using it in public copy is out.
- The active ingredient. Naming the drug by its ingredient is the same breach as naming the brand. You cannot get around the rule by being technical.
- A clear reference. "The weekly injection everyone is talking about" can point to one product so plainly that it counts as naming it. Hinting is still advertising.
- Any channel. Your website, landing pages, blog posts, social media, emails, even a meta description or an image caption. There is no safe channel.
One more trap. A medicine being famous does not make it fair game. The more recognisable the product, the easier it is to point to it without naming it, and the TGA treats a clear reference the same as the name.
What can you say instead?
Here is the good news. The rule limits what you can say about the product. It does not stop you marketing the service. You can build a page that brings in enquiries without ever naming a medicine.
The safe pattern is simple: advertise the consultation, factually.
- The service. You can say your clinic offers appointments to discuss a health concern, who provides them, and what happens at the visit.
- The process. You can explain that a doctor assesses the person and discusses suitable options, and that any treatment is decided by the doctor if it is clinically appropriate.
- The practice details. Location, hours, qualifications, and how to book.
What you describe is what the clinician does, the assessment and the consultation. What you never describe is the specific medicine, the outcome it produces, or a reason to want that drug. Sell the appointment, not the prescription.
Say this, not that: five rewrites
Here are five lines that breach the rule, each with a compliant version. Every "say this" line is written to the full standard, so it works for the TGA and, where a service is involved, for the AHPRA advertising guidelines too.
| Not this (breach) | Say this (compliant) | Why it works |
|---|---|---|
| "Get [prescription medicine] online. Start today." | "Book a consultation with our doctors to discuss your options." | Advertises the appointment. Names no medicine and promises no outcome. |
| "Ask us about the injection everyone is talking about." | "Our doctors can talk you through suitable options at your appointment." | No clear reference to a single product. Describes the consultation. |
| "[Active ingredient] now available, no GP referral needed." | "Appointments available with our team. A doctor decides on any treatment if it is clinically appropriate." | No ingredient named. Keeps the doctor as the decision-maker and respects normal care. |
| "This medication melts fat fast, guaranteed." | "We offer consultations to discuss your health goals and the options that may suit you." | No product, no outcome claim, and no guarantee. |
| "Skip the wait. Same-day scripts from our pharmacy partner." | "Appointments are usually available within a few days. Your doctor will discuss next steps with you." | No urgency, no prescription-as-endpoint, and no pharmacy channelling. |
Does "educational content" get around it?
This is the question I get most, and the answer is no.
There is no "it was just education" exemption. The test is whether the content promotes the use or supply of the medicine. A blog post that names a prescription drug, names the clinic, and ends with a "book now" link is advertising, whatever heading sits on top of it. Putting a "general information only" line at the bottom does not change what the page does.
You can absolutely publish genuine education. You can write about a health condition, about how a type of treatment works in general terms, or about what to expect from a consultation. The line is crossed when the content points the reader to a specific prescription product and nudges them to get it. Keep the education about the condition and the care, not the drug.
Quick test: remove the clinic name and the booking link from your page. Does it still read like a reason to go and ask for a specific medicine? If yes, it is an ad for that medicine, and the disclaimer will not save it.
Who is liable when it goes wrong?
Breaching this rule is not a small risk. The TGA can issue warnings and infringement notices, and it can take court action. Penalties for advertising offences are significant and can run into the millions for serious or repeated breaches.
The detail that matters for marketers is who carries the risk. The advertiser is liable, and the law reads "advertiser" broadly. That includes the agency and the copywriter who wrote the page, not only the business that runs the clinic. If you write or approve the copy, you share the risk with the client.
For a registered practitioner there is a second door. The same breach can become a complaint to AHPRA, which can affect their registration. One careless line can trigger two separate problems at once.
The fix is not to write less. It is to write to the rule from the first draft, so the page still ranks and converts without putting the client or yourself at risk. That is the whole job of compliance-first copy.
